Marumo F, Shichiri M, Emori T, Ando K
Second Department of Internal Medicine, Tokyo Medical and Dental University, Japan.
Clin Nephrol. 1992 Oct;38(4):203-8.
The immunoreactivity of plasma and urine atrial natriuretic peptide (ANP) was measured in patients with renal disease and in healthy volunteers. The molecular forms of ANP in these subjects were estimated by gel permeation chromatography and reverse phase high performance liquid chromatography. No significant increase in plasma ANP was observed in patients with nephrotic syndrome or non-oliguric chronic renal failure compared to healthy volunteers. However, plasma ANP levels were significantly increased in patients on hemodialysis (normal 18.6 +/- 11.4 fmol/ml; hemodialysis 91.2 +/- 69.9 fmol/ml, p < 0.01). Chromatographic analyses revealed that plasma ANP consisted of only alpha-ANP or combined alpha- and gamma-ANP in healthy volunteers and in nephrotic patients, whereas beta-ANP frequently appeared in the plasma of both dialyzed and non-dialyzed chronic renal failure patients. Excreted forms, except in subjects free from renal disease where gamma-ANP may serve as a potential marker of glomerular injury in humans.
对肾病患者和健康志愿者测定了血浆和尿液中心房钠尿肽（ANP）的免疫反应性。通过凝胶渗透色谱法和反相高效液相色谱法对这些受试者体内ANP的分子形式进行了评估。与健康志愿者相比，肾病综合征或非少尿型慢性肾衰竭患者的血浆ANP未观察到显著升高。然而，血液透析患者的血浆ANP水平显著升高（正常为18.6±11.4 fmol/ml；血液透析患者为91.2±69.9 fmol/ml，p<0.01）。色谱分析显示，健康志愿者和肾病患者的血浆ANP仅由α-ANP或α-ANP与γ-ANP的组合组成，而β-ANP经常出现在透析和未透析的慢性肾衰竭患者血浆中。排泄形式方面，除了无肾脏疾病的受试者外，γ-ANP可能是人类肾小球损伤的潜在标志物。
